← All trials
NCT04981691
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Jan 9, 2022
- Completion date
- Jul 9, 2022
- First posted
- Jul 29, 2021
- Last posted
- Sep 17, 2021
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiao Tong UniversityLead sponsor
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- UTC Therapeutics Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.